Security
Atara Biotherapeutics, Inc. Common Stock · ATRA
ATRANASDAQCommon stockCurrentCIK 1604464Updated Oct 6, 2026
ATRA price & chart
Loading TradingView…
NASDAQ:ATRA on TradingView ↗About the company
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.
In the news
ATRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 22 Deadline in Securities Class Action - ATRA ↗
ATRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 22 Deadline in Securities Class Action - ATRA ↗
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA ↗
Recent filings
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
3 filing
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 30,167,000Source | 142,706,000Source | 21,024,000Source | 36,902,000Source | 117,284,000Source | 19,997,000Source | 62,038,000Source | 165,272,000Source | 20,235,000Source | 109,098,000Source | 165,504,000Source | 376,420,000Source |
| Property, Plant and Equipment, NetUSD | 147,000Source | 1,661,000Source | 41,000Source | 176,000Source | 2,317,000Source | 55,000Source | 285,000Source | 2,989,000Source | 73,000Source | 1,294,000Source | 3,856,000Source | 6,300,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,742,000Source | 46,453,000Source | 3,221,000Source | 16,903,000Source | 31,314,000Source | 8,360,000Source | 13,841,000Source | 35,087,000Source | 8,482,000Source | 25,030,000Source | 25,841,000Source | 92,942,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,913,000Source | 1,335,000Source | 318,000Source | 0Source | 2,422,000Source | 0Source | 8,875,000Source | 35,834,000Source | 1,253,000Source | 1,482,000Source | 34,108,000Source | 40,221,000Source |
| Inventory, NetUSD | 0Source | 13,980,000Source | — | 0Source | 18,749,000Source | — | 0Source | 16,084,000Source | 0Source | 10,655,000Source | 9,706,000Source | 1,586,000Source |
| Assets, CurrentUSD | 18,432,000Source | 91,855,000Source | 13,530,000Source | 24,772,000Source | 62,410,000Source | 12,173,000Source | 27,182,000Source | 106,434,000Source | 12,212,000Source | 64,894,000Source | 101,869,000Source | 295,080,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,707,000Source | 45,833,000Source | 6,688,000Source | 11,027,000Source | 48,948,000Source | 6,879,000Source | 31,727,000Source | 51,981,000Source | 7,064,000Source | 39,807,000Source | 54,935,000Source | 68,022,000Source |
| Other Assets, NoncurrentUSD | 881,000Source | 3,357,000Source | 765,000Source | 927,000Source | 3,609,000Source | 890,000Source | 2,844,000Source | 3,868,000Source | 886,000Source | 3,103,000Source | 4,844,000Source | 7,018,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 66,801,000Source | 233,245,000Source | 58,020,000Source | 71,943,000Source | 228,152,000Source | 57,309,000Source | 117,110,000Source | 263,580,000Source | 58,737,000Source | 206,381,000Source | 264,735,000Source | 249,780,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 0Source | 1,000Source | 1,000Source | 12,000Source | 1,000Source | 1,000Source | 11,000Source | 10,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,018,459,000Source | -2,041,860,000Source | -2,030,844,000Source | -2,014,156,000Source | -2,019,951,000Source | -2,026,010,000Source | -2,016,543,000Source | -2,000,902,000Source | -2,021,865,000Source | -2,054,553,000Source | -1,969,150,000Source | -1,693,024,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,000Source | 22,000Source | -2,000Source | 0Source | -14,000Source | 0Source | 0Source | -55,000Source | 1,000Source | 8,000Source | -204,000Source | -2,067,000Source |
| Stockholders' Equity Attributable to ParentUSD | -36,634,000Source | -90,539,000Source | -36,996,000Source | -35,041,000Source | -110,868,000Source | -37,312,000Source | -55,072,000Source | -98,308,000Source | -38,502,000Source | -97,283,000Source | -99,231,000Source | 126,640,000Source |
| Additional Paid in Capital, Common StockUSD | 1,981,822,000Source | 1,951,298,000Source | 1,993,849,000Source | 1,979,114,000Source | 1,909,097,000Source | 1,988,697,000Source | 1,961,470,000Source | 1,902,637,000Source | 1,983,361,000Source | 1,957,261,000Source | 1,870,112,000Source | 1,821,721,000Source |
| Liabilities and EquityUSD | 30,167,000Source | 142,706,000Source | 21,024,000Source | 36,902,000Source | 117,284,000Source | 19,997,000Source | 62,038,000Source | 165,272,000Source | 20,235,000Source | 109,098,000Source | 165,504,000Source | 376,420,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 18,057,000Source | 155,979,000Source | 6,847,000Source | 14,563,000Source | 148,267,000Source | 5,645,000Source | 47,892,000Source | 180,690,000Source | 14,922,000Source | 134,574,000Source | 142,226,000Source | 78,916,000Source |
| Operating Lease, Liability, CurrentUSD | 1,953,000Source | 13,652,000Source | 1,097,000Source | 2,242,000Source | 13,024,000Source | 1,014,000Source | 12,846,000Source | 13,087,000Source | 1,028,000Source | 12,879,000Source | 11,264,000Source | 12,806,000Source |
| Accounts Payable, CurrentUSD | 318,000Source | 2,146,000Source | 824,000Source | 1,762,000Source | 5,253,000Source | 637,000Source | 1,384,000Source | 2,854,000Source | 127,000Source | 4,367,000Source | 3,684,000Source | 6,871,000Source |
| Operating Lease, Liability, NoncurrentUSD | 15,005,000Source | 35,243,000Source | 8,782,000Source | 15,426,000Source | 38,703,000Source | 9,076,000Source | 26,708,000Source | 42,197,000Source | 9,347,000Source | 29,914,000Source | 45,693,000Source | 58,064,000Source |
| Other Liabilities, NoncurrentUSD | 1,763,000Source | 3,969,000Source | 1,885,000Source | 1,732,000Source | 4,167,000Source | 1,829,000Source | 3,127,000Source | 4,401,000Source | 1,795,000Source | 3,269,000Source | 4,631,000Source | 5,564,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,552,000Source | 8,059,000Source | 2,155,000Source | 4,783,000Source | 11,187,000Source | 1,754,000Source | 9,498,000Source | 18,203,000Source | 1,798,000Source | 6,027,000Source | 19,007,000Source | 7,435,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,656,000Source | 8,747,000Source | 11,607,000Source | 15,220,000Source |
| Short-term InvestmentsUSD | 7,970,000Source | 20,736,000Source | 6,652,000Source | 5,420,000Source | 3,978,000Source | — | 0Source | 11,152,000Source | 0Source | 17,466,000Source | 25,884,000Source | 149,877,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -4,303,000Source | -21,909,000Source | -4,834,000Source | 2,387,000Source | -4,145,000Source | 38,010,000Source | 32,688,000Source | -85,403,000Source | -276,126,000Source | -228,302,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 749,000Source | 4,209,000Source | 9,752,000Source | 27,001,000Source | 45,386,000Source | 53,838,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -1,253,000Source | 7,393,000Source | -229,000Source | -32,626,000Source | -6,113,000Source | 39,235,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 0Source | -10,655,000Source | -10,655,000Source | 4,434,000Source | 8,120,000Source | 1,586,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 510,000Source | -2,983,000Source | -4,240,000Source | 687,000Source | -3,130,000Source | -9,211,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,073,000Source | -28,138,000Source | -50,940,000Source | -68,717,000Source | -192,977,000Source | -270,430,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 17,199,000Source | 18,148,000Source | 8,624,000Source | 123,866,000Source | 202,956,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | 246,000Source | 1,223,000Source | 4,193,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | 0Source | — | 0Source | 94,000Source | 623,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,951,000Source | -250,000Source | 16,098,000Source | 59,282,000Source | 2,010,000Source | 53,084,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | -1,000Source | -7,000Source | -13,000Source | -192,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 5,742,000Source | 46,599,000Source | 3,221,000Source | 16,903,000Source | 8,360,000Source | 13,987,000Source | 8,482,000Source | 25,176,000Source | 25,987,000Source | 93,088,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 105,000Source | 66,000Source | 286,000Source | 685,000Source | 447,000Source | 335,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 0Source | 190,000Source | 24,000Source | 2,000Source | 19,000Source |
| Additional Financial Items | ||||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | 814,000Source | 852,000Source | 3,578,000Source | 4,109,000Source | 4,792,000Source | — |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,225,000Source | 6,422,000Source | 394,000Source | 2,801,000Source | 749,000Source | 4,209,000Source | 9,752,000Source | 27,001,000Source | 45,386,000Source | 53,838,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 13,000Source | 14,000Source | 58,000Source | 67,000Source | 79,000Source | — |
| DepreciationUSD | — | — | — | 600,000Source | — | — | — | 300,000Source | 400,000Source | 2,700,000Source | 3,700,000Source | — |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 50,237,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 50,237,000Source |
| Gain (Loss) on Sale of PropertiesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 50,237,000Source |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | — | — | — | — | — | — | — | — | — | 50,200,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | 3,818,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,987,000Source | 10,421,000Source | 3,814,000Source | 6,514,000Source | 3,597,000Source | 11,475,000Source | 26,253,000Source | 39,886,000Source | 50,908,000Source | 71,553,000Source |
| Income Tax Expense (Benefit)USD | — | — | 28,000Source | -17,000Source | 1,000Source | 3,000Source | 0Source | 0Source | 31,000Source | -12,000Source | 15,000Source | 12,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,303,000Source | -21,909,000Source | -4,834,000Source | 2,387,000Source | -4,145,000Source | 38,010,000Source | 32,688,000Source | -85,403,000Source | -276,126,000Source | -228,302,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 344,086,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | 0Source | 4,130,000Source | 4,130,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 4,000Source | 555,000Source | 0Source | 22,000Source | 0Source | -11,000Source | -34,000Source | 528,000Source | -246,000Source | 1,986,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 729,000Source | 152,000Source | 114,000Source | 810,000Source | 776,000Source | 792,000Source | 3,174,000Source | 1,965,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 2,951,000Source | 0Source | 1,471,000Source | 9,348,000Source | 2,136,000Source | 21,891,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 40,190,000Source | — | — | — | — | 120,772,000Source | 128,940,000Source | 8,573,000Source | — |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,453,000Source | 40,190,000Source | 630,000Source | 17,575,000Source | 516,000Source | 98,149,000Source | 120,772,000Source | 128,940,000Source | — | — |
| Operating Income (Loss)USD | — | — | -3,574,000Source | -21,757,000Source | -4,720,000Source | 3,197,000Source | -3,369,000Source | 38,802,000Source | 35,862,000Source | -83,438,000Source | -276,006,000Source | -280,513,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 4,000Source | 555,000Source | 0Source | 22,000Source | 0Source | -11,000Source | -34,000Source | 528,000Source | -246,000Source | 1,986,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -4,275,000Source | -21,926,000Source | -4,833,000Source | 2,390,000Source | -4,145,000Source | 38,010,000Source | 32,719,000Source | -85,415,000Source | -276,111,000Source | -228,290,000Source |
| Income Tax Expense (Benefit)USD | — | — | 28,000Source | -17,000Source | 1,000Source | 3,000Source | 0Source | 0Source | 31,000Source | -12,000Source | 15,000Source | 12,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,303,000Source | -21,909,000Source | -4,834,000Source | 2,387,000Source | -4,145,000Source | 38,010,000Source | 32,688,000Source | -85,403,000Source | -276,126,000Source | -228,302,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.32Source | -2.93Source | -0.32Source | 0.2Source | -0.29Source | 3.53Source | 2.61Source | -11.41Source | -2.61Source | -2.24Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.32Source | -2.93Source | -0.32Source | 0.19Source | -0.29Source | 3.5Source | 2.57Source | -11.41Source | -2.61Source | -2.24Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 13,564,000Source | 7,466,000Source | 15,033,000Source | 12,197,000Source | 14,081,000Source | 10,764,000Source | 12,544,000Source | 7,488,000Source | 105,912,000Source | 101,990,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 13,564,000Source | 7,466,000Source | 15,033,000Source | 12,310,000Source | 14,081,000Source | 10,851,000Source | 12,718,000Source | 7,488,000Source | 105,912,000Source | 101,990,000Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 7,027,000Source | 61,947,000Source | 5,350,000Source | 14,378,000Source | 3,885,000Source | 59,347,000Source | 84,910,000Source | 212,378,000Source | 284,579,000Source | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 31,000Source | -12,000Source | 15,000Source | 12,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 29,000Source | 1,795,000Source | 2,116,000Source | 5,051,000Source | 4,829,000Source | 5,653,000Source |
| General and Administrative ExpenseUSD | — | — | 3,987,000Source | 10,421,000Source | 3,814,000Source | 6,514,000Source | 3,597,000Source | 11,475,000Source | 26,253,000Source | 39,886,000Source | 50,908,000Source | 71,553,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 32,737,000Source | -85,311,000Source | -276,360,000Source | -228,395,000Source |
| Interest ExpenseUSD | — | — | 909,000Source | 1,183,000Source | 191,000Source | 972,000Source | 830,000Source | 1,017,000Source | 3,792,000Source | 4,615,000Source | 5,285,000Source | — |
| Interest Income, OperatingUSD | — | — | 204,000Source | 459,000Source | 78,000Source | 143,000Source | 54,000Source | 236,000Source | 683,000Source | 2,110,000Source | 5,426,000Source | — |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 344,086,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 729,000Source | 152,000Source | 114,000Source | 810,000Source | 776,000Source | 792,000Source | 3,174,000Source | 1,965,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 2,925,000Source | 43,924,000Source | 1,345,000Source | 7,310,000Source | 164,000Source | 27,433,000Source | 37,445,000Source | 151,483,000Source | 224,785,000Source | 272,533,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 40,190,000Source | — | — | — | — | 120,772,000Source | 128,940,000Source | 8,573,000Source | — |
Filing attachments
atra-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 atra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress Productive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87% THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr vir…
Read attachment ↗ea029458501ex4-6.htm · S-8 · 2026-06-12
Exhibit 4.6 FIRST AMENDMENT TO ATARA BIOTHERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN WHEREAS, Atara Biotherapeutics, Inc. (the “Company”) has heretofore adopted the Atara Biotherapeutics, Inc. 2024 Equity Incentive Plan (the “Plan”); and WHEREAS, the Company wishes to amend the Plan to increase the number of shares of common stock of the Company, par value $0.0001 per share, available for issuance under the Plan. NOW, THEREFORE, the Plan shall be amended, effective as the date on which th…
Read attachment ↗atra-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 atra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress Productive meeting held with the FDA; planning for tabelecleucel BLA resubmission Operating efficiencies and ATM proceeds extend cash runway into mid-2027 THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat…
Read attachment ↗atra-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 atra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today provided an update following the recent Type A meeting with the U.S. Food and Drug Admin…
Read attachment ↗d34257dex991.htm · 8-K · 2026-01-12
Exhibit 99.1 Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO ™ (tabelecleucel) U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) THOUSAND OAKS, Calif. - (BUSINESS WIRE) - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food …
Read attachment ↗